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When designing a study to develop a new prediction model with binary or
time-to-event outcomes, researchers should ensure their sample size is adequate
in terms of the number of participants (n) and outcome events (E) relative to
the number of predictor parameters (p) considered for inclusion. We propose
that the minimum values of n and E (and subsequently the minimum number
of events per predictor parameter, EPP) should be calculated to meet the follow-
ing three criteria: (i) small optimism in predictor effect estimates as defined by
a global shrinkage factor of ≥ 0.9, (ii) small absolute difference of ≤ 0.05 in the
model's apparent and adjusted Nagelkerke's R2, and (iii) precise estimation of
the overall risk in the population. Criteria (i) and (ii) aim to reduce overfitting
conditional on a chosen p, and require prespecification of the model's antici-
pated Cox-Snell R2, which we show can be obtained from previous studies. The
values of n and E that meet all three criteria provides the minimum sample
size required for model development. Upon application of our approach, a new
diagnostic model for Chagas disease requires an EPP of at least 4.8 and a new
prognostic model for recurrent venous thromboembolism requires an EPP of at
least 23. This reinforces why rules of thumb (eg, 10 EPP) should be avoided.
Researchers might additionally ensure the sample size gives precise estimates of
key predictor effects; this is especially important when key categorical predic-
tors have few events in some categories, as this may substantially increase the
numbers required.
KEYWORDS
binary and time-to-event outcomes, logistic and Cox regression, multivariable prediction model,
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1 INTRODUCTION
Statistical models for risk prediction are needed to inform clinical diagnosis and prognosis in healthcare.1-3 For example,
they may be used to predict an individual's risk of having an undiagnosed disease or condition (“diagnostic prediction
model”), or to predict an individual's risk of experiencing a specific event in the future (“prognostic prediction model”).
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They are typically developed using a multivariable regression framework, such as logistic or Cox (proportional hazards)
regression, which provides an equation to estimate an individual's risk based on their values of multiple predictors (such
as age and smoking, or biomarkers and genetic information). Well-known examples are the Wells score for predicting
the presence of a pulmonary embolism4,5; the Framingham risk score and QRISK2,6,7 which estimate the 10-year risk
of developing cardiovascular disease (CVD); and the Nottingham Prognostic Index, which predicts the 5-year survival
probability of a woman with newly diagnosed breast cancer.8,9
Researchers planning or designing a study to develop a newmultivariable prediction model must consider sample size
requirements for their development data set. Our related paper considered this issue for predictionmodels of a continuous
outcomeusing linear regression.10 Here, we focus on binary and time-to-event outcomes, such as the risk of already having
a pulmonary embolism, or the risk of developing CVD in the next 10 years. In this situation, the effective sample size is
often considered to be the number of outcome events (eg, the number with existing pulmonary embolism, or the number
diagnosed with CVD during follow-up). In particular, a well-used “rule of thumb” for sample size is to ensure at least
10 events per candidate predictor (variable),11-13 where “candidate” indicates a predictor in the development data set that
is considered, before any variable selection, for inclusion in the final model. Note that, if a predictor is categorical with
three of more categories, or continuous and modelled as a nonlinear trend, then including the predictor will require two
or more parameters being included in the model. Therefore, we refer to events per predictor parameter (EPP) here, rather
than events per variable.
The 10 EPP rule has generated much debate. Some authors claim that the EPP can sometimes be lowered below 10.14
In contrast, Harrell generally recommends at least 15 EPP,15 and others identify situations where at least 20 EPP or up
to 50 EPP are required.16-19 However, a concern is that any blanket rule of thumb is too simplistic, and that the number
of participants required will depend on many intricate aspects, including the magnitude of predictor effects, the overall
outcome risk, the distribution of predictors, and the number of events for each category of categorical predictors.16 For
example, Courvoisier et al20 concluded that “There is no single rule based on EPP that would guarantee an accurate
estimation of logistic regression parameters.” A new sample size approach is needed to address this.
In this article, we propose the sample size (n) and number of events (E) in the model development data set must, at
the very least, meet the following three criteria: (i) small optimism in predictor effect estimates as defined by a global
shrinkage factor of≥ 0.9, (ii) small absolute difference of≤ 0.05 in themodel's apparent and adjusted Nagelkerke'sR2, and
(iii) precise estimation of the overall risk or rate in the population (or similarly, precise estimation of the model intercept
when predictors are mean centred). The values of n and E (and subsequently EPP) that meet all three criteria provide the
minimumvalues required formodel development. Criteria (i) and (ii) aim to reduce the potential for a developedmodel to
be overfitted to the development data set at hand. Overfitting leads to model predictions that are more extreme than they
ought to be when applied to new individuals, and most notably occurs when the number of candidate predictors is large
relative to the number of outcome events. A consequence is that a developed model's apparent predictive performance
(as observed in the development data set itself) will be optimistic, and its performance in new data will usually be lower.
Therefore, it is good practise to reduce the potential for overfitting when developing a prediction model,15 which criteria
(i) and (ii) aim to achieve. In addition, criterion (iii) aims to ensure that the overall risk (eg, by a key time point for
prediction) is estimated precisely, as fundamentally, before tailoring predictions to individuals, a model must be able to
reliably predict the overall or mean risk in the target population.
The article is structured as follows. Section 2 introduces our proposed criterion (i), for which key concepts of a global
shrinkage factor and the Cox-Snell R2 are introduced.21 The latter needs to prespecified to utilise our sample size formula,
and so in Section 3, we suggest how realistic values of the Cox-Snell R2 can be obtained in advance of any data collection,
eg, by using published information from an existing model in the same field, including values of the C statistic or alter-
native R2 measures. Extension to criteria (ii) and (iii) is then made in Section 4. Section 5 then provides two examples,
which demonstrate our sample size approach for diagnostic and prognostic models. Section 6 raises a potential additional
criteria to consider: ensuring precise estimates of key predictor effects, to help ensure precise predictions across the entire
spectrum of predicted risk. Section 7 concludes with discussion.
2 SAMPLE SIZE REQUIRED TO MINIMISE OVERFITTING OF PREDICTOR
EFFECTS
To adjust for overfitting during model development (and thereby improve the model's predictive performance in
new individuals), statistical methods for penalisation of predictor effect estimates are available, where regression
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coefficients are shrunk toward zero from their usual estimated value (eg, from standard maximum likelihood
estimation).22-26 Van Houwelingen notes that “… shrinkage works on the average but may fail in the particular unique
problem on which the statistician is working.”22 Therefore, it is important to minimise the potential for overfitting during
model development, and this criterion forms the basis of our first sample size calculation. Our approach is motivated
by the concept of a global shrinkage factor (a measure of overfitting), and so we begin by introducing this, before then
deriving a sample size formula.
2.1 Concept of a global shrinkage for logistic and Cox regression
The concept of shrinkage (penalisation) was outlined in our accompanying paper,10 and is explained in detail
elsewhere.1,15,27 Here, we focus on using a global shrinkage factor (S), sometimes referred to as a uniform shrinkage
factor. Consider a logistic regressionmodel has been fitted using standardmaximum likelihood estimation (ie, traditional
and unpenalised estimation). Subsequently, S can be estimated (eg, using bootstrapping,28 or via a closed-form solution;
see Section 2.2) and applied to the estimated predictor effects, so that the revised model is
𝑙𝑛
(
pi
1 − pi
)
= 𝛼∗ + S
(
𝛽1X1i + 𝛽2X2i + 𝛽3X3i + · · ·
)
. (1)
Here, pi is the outcome probability for the ith individual, the 𝛽 terms denote the original predictor effect estimates
(ln odds ratios) frommaximum likelihood, and 𝛼* is the intercept that has been re-estimated (after shrinkage of predictor
effects) to ensure perfect calibration-in-the-large, such that, the overall predicted risk still agrees with the overall observed
risk in the development data set (for details on how to do this, we refer to the works of Harrell15 and Steyerberg1). Simi-
larly, after fitting a proportional hazards (Cox) regression model using standard maximum likelihood, the model can be
revised using
hi(t) = h0(t)∗ exp
(
S
(
𝛽1X1i + 𝛽2X2i + 𝛽3X3i + · · ·
))
, (2)
where hi(t) is the hazard rate of the outcome over time (t) for the ith individual and ho(t)* is the baseline hazard function
re-estimated (after shrinkage of predictor effects) to ensure the predicted and observed outcome rates agree for the devel-
opment data set as whole. Compared to the original (nonpenalised) models, the revised models (1) and (2) will shrink
predicted probabilities away from zero and one, toward the overall mean outcome probability in the development data set.
Example of a global shrinkage factor
Van Diepen et al developed a prognostic model for 1-year mortality risk in patients with diabetes starting dialysis.29
They use a logistic regression framework, with backwards selection to choose predictors in a dataset of 394 patients with
84 deaths by 1 year, and the estimatedmodel is shown in Table 1. To examine overfitting, the authors use bootstrapping to
estimate a global shrinkage factor of 0.903, indicating that the originalmodel was slightly overfitted to the data. Therefore,
a revised prediction model was produced by multiplying the original 𝛽 coefficients (ln odds ratios) from the original
logistic regression model by a global shrinkage factor of S = 0.903.
TABLE 1 Example of global shrinkage applied to a prognostic model for 1-year mortality risk in patients with diabetes starting
dialysis29
Developed (unpenalised) model Final (penalised) model adjusted for overfitting
Intercept ?̂? 𝜶*
1.962 1.427
Predictor 𝜷 S𝜷 = 0.903𝜷
Age (years) 0.047 0.042
Smoking 0.631 0.570
Macrovascular complications 1.195 1.078
Duration of diabetes mellitus (years) 0.026 0.023
Karnofsky scale −0.043 −0.039
Haemoglobin level (g/dl) −0.186 −0.168
Albumin level (g/l) −0.060 −0.054
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2.2 Expressing sample size in terms of a global shrinkage factor
Bootstrapping is an excellent way to calculate the shrinkage factor postestimation, but (as it is a resampling method) is
not useful for us in advance of data collection. An alternative approach to calculating a global shrinkage factor is to use
the closed form “heuristic” shrinkage factor of Van Houwelingen and Le Cessie,23 defined by
SVH = 1 −
p
LR , (3)
where p is the total number of predictor parameters for the full set of candidate predictors (ie, all those considered for
inclusion in the model) and LR is the likelihood ratio (chi-squared) statistic for the fitted model defined as
LR = −2 (lnLnull − lnLmodel) , (4)
where lnLnull is the log-likelihood of amodelwith no predictors (eg, intercept-only logistic regressionmodel), and lnLmodel
is the log-likelihood of the finalmodel. In our related paper on linear regression,weused theCopas shrinkage estimate that
is similar to Equation (3), butwith p replaced by p+2. In our experience, SVH performs better for generalised linearmodels
than the Copas estimate, with SVH further from 1 and closer to the corresponding estimate obtained from bootstrapping.
Copas also notes that, unlike for linear regression, a formal justification for replacing p by p + 2 in Equation (2) has not
been proved for logistic regression.30
Hence, we use Equation (3) as our shrinkage estimate (ie, our measure of overfitting) for logistic and Cox regression
models, which now motivates our sample size approach to meet criterion (i). First, let us re-express the right-hand side
of Equation (3) in terms of sample size (n), number of candidate predictor parameters (p), and the Cox-Snell generalised
R2.21 The latter is also known as the maximum likelihood R2, the likelihood ratio R2, or Magee's R2,31 and it provides a
generalisation (eg, to logistic and Cox regression models) of the well-known proportion of variance explained for linear
regression models. Let us use R2CS_app to denote the apparent (“app”) estimate of a prediction model's Cox-Snell (“CS”) R
2
performance as obtained from the model development data set. It can be shown (eg, see the works of Magee31 or Hendry
and Nielsen32) that the LR statistic can be expressed in terms of the sample size (n) and R2CS_app as follows:
LR = −n ln
(
1 − R2CS_app
)
. (5)
This leads to the Cox-Snell generalised definition of the apparent R2 expressed in terms of the LR value for any regression
model, including logistic and Cox regression
R2CS_app = 1 − exp
(−LR
n
)
. (6)
Applying Equation (5) within Equation (3), the Van Houwelingen and Le Cessie shrinkage factor becomes
SVH = 1 +
p
n ln
(
1 − R2CS_app
) . (7)
2.3 Criterion (i): calculating sample size to ensure a shrinkage factor ≥ 0.9
Equation (7) provides a closed-form solution for the expected shrinkage conditional on n, p, and R2CS_app. Therefore, if
we could specify a realistic value for R2CS_app in advance of our study starting, we could identify values of n and p that
correspond to a desired shrinkage factor (eg, 0.9), thus informing the required sample size. However, a major problem is
that R2CS_app is a postestimation measure of model fit, whereas for a sample size calculation, this needs to be specified in
advance of collecting the data when designing a new study. Furthermore, due to overfitting in the model development
data set, the observed R2CS_app is generally an upwardly biased (optimistic) estimate of the Cox-Snell R
2 as it is estimated
in the same data used to develop the model. Thus, in new data, the actual Cox-Snell R2 peformance is likely to be lower.
Therefore, we need to re-express SVH in terms of R2CS_adj, an adjusted (approximately unbiased) estimate of the model's
expectedR2CS performance in new individuals from the samepopulation. In otherwords,R
2
CS_adj is amodification ofR
2
CS_app
to adjust for optimism (caused by overfitting) in the model development data set. For generalised linear models such as
logistic regression, Mittlboeck and Heinzl suggest that R2CS_adj can be obtained by
33
R2CS_adj = SVHR
2
CS_app (8)
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as the expected value of this R2CS_adj corresponds to the underlying population value.
33 By rearranging Equation (8), we
can express R2CS_app in terms of R
2
CS_adj
R2CS_app =
R2CS_adj
SVH
. (9)
Applying Equation (9) within Equation (7), we can now express SVH in terms of R2CS_adj, rather than R
2
CS_app
SVH = 1 +
p
n ln
(
1 −
R2CS_adj
SVH
) . (10)
Finally, a simple rearrangement of Equation (10) leads to a closed-form solution for the required sample size to develop
a prediction model conditional on p, SVH and R2CS_adj
n = p
(SVH − 1) ln
(
1 −
R2CS_adj
SVH
) . (11)
For example, for developing a new logistic regression model based on up to 20 candidate predictor parameters with an
anticipated R2CS_adj of at least 0.1, then to target an expected shrinkage of 0.9, we need a sample size of
n = p
(SVH − 1) ln
(
1 −
R2CS_adj
SVH
) = 20
(0.9 − 1) ln
(
1 − 0.10.9
) = 1698,
and thus 1698 individuals.
2.4 Translating the calculated sample size to the number of events and EPP
Itmay be surprising that the overall outcomeproportion (or overall outcome rate) is not directly included in the right-hand
side of the sample size Equation (11), especially because the total number of events, E, (which depends on the outcome
proportion or rate) is often considered the effective sample size for binary and time-to-event outcomes.15 However, the
outcome proportion (rate) is indirectly accounted for in the sample size calculation via the chosen R2CS_adj, as the max-
imum value of R2CS_adj for the intended population of the model depends on the overall outcome proportion (rate) for
that population. As the outcome proportion decreases, the maximum value of R2CS decreases. This is explained further in
Section 3.4. Therefore, after n is derived from the sample size equation (11),E can be obtained by combining the calculated
n with the outcome proportion (rate) for the intended population. Similarly, EPP can be obtained.
For example for binary outcomes, E = n𝜙 and EPP = n𝜙/p, where 𝜙 is the overall outcome proportion in the target
population (ie, the overall prevalence for diagnostic models, or the overall cumulative incidence by a key time point
for prognostic models). In our aforementioned hypothetical example, where 1698 subjects were needed based on an
R2CS_adj of 0.1 and SVH of 0.9, then if the intended setting has 𝜙 of 0.1 (ie, overall outcome risk is 10%), the required
E = 1698 × 0.1 = 169.8. With 20 predictor parameters, the required EPP = (1698 × 0.1)/20= 8.5. However, if the intended
setting has 𝜙 of 0.3, then E= 509.4 and EPP= 25.5. The big change in EPP is because, although the chosen value of R2CS_adj
is fixed at 0.1, the maximum value of R2CS is much higher for the setting with the higher outcome proportion.
We can explain this further using Nagelkerke's “proportion of total variance explained”,34 which is calculated as
R2CS_adj∕max(R
2
CS). If two models have the same R
2
CS_adj (say at 0.1, as in the aforementioned examples), then Nagelkerke's
measure of predictive performance will be lower for the model whose setting has a higher outcome proportion, as the
max(R2CS) is larger in that setting.Models with lower performance have larger overfitting concerns,
22 and therefore require
larger EPP to minimise overfitting than models with high performance. Hence, explaining why EPP was larger when 𝜙
was 0.3 compared with 0.1 in the aforementioned example. This highlights that a blanket rule of thumb (such as at least
10 EPP) is unlikely to be sensible to meet criterion (i), as the actual EPP depends on the setting/population of interest
(which dictates the overall outcome proportion or rate) and expected model performance.
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3 HOW TO PRESPECIFY R𝟐CS_adj BASED ON PREVIOUS INFORMATION
Our sample size proposal in Equation (11) requires researchers to provide a value for the model's R2CS_adj, that is, to pre-
specify the anticipated Cox-Snell R2 value if the model was applied to new individuals. How should this be done? We
recommend using R2CS_adj values from previous predictionmodel studies for the same (or similar) population, considering
the same (or similar) outcomes and time points of interest. For example, the researcher could consult systematic reviews
of existing models and their performance, which are also increasingly available,35 or registries that record the prediction
models available in a particular field.36
Often, a newpredictionmodel is developed specifically to update or improve upon the performance of an existingmodel,
by using additional predictors. Then, the existing model's R2CS_adj could be used as a lower bound for the new model's
anticipated R2CS_adj. In this situation, if the apparent Cox-Snell estimate, R
2
CS_app, is available in an article describing the
development of the existing model, then its R2CS_adj can be derived using Equation (8) as long as the study's n and p can
also be obtained. In addition, as in van Diepen et al's example (Table 1), a global shrinkage factor may be reported directly
for an existing model development study, and if so, R2CS_adj can be derived from a simple rearrangement of Equation (10),
again as long as the study's n and p are also available.
Note that, if R2CS_app is available from an external validation study of an existing model, there is no need for adjustment
(ie, R2CS_app = R
2
CS_adj), as the validation dataset provides a direct estimate of the model's performance in new individuals
(free from overfitting concerns as there is no model development therein).
Other options to obtain R2CS_adj from the existing literature are now described. For guidance on choosing an R
2
CS_adj value
in the absence of any prior information, please see our discussion.
3.1 Using the LR statistic to derive the Cox-Snell R𝟐adj
If the R2CS_app or R
2
CS_adj is not available in the publication of an existingmodel, the LR valuemay be reported, which would
allow R2CS_app to be derived using Equation (6), then SVH for the model derived using Equation (7) (assuming the model's
n and p are also provided), and finally R2CS_adj using Equation (8).
Sometimes the log-likelihood of the final model (lnLmodel) is reported, but not the LR value itself. In this situation, the
researcher should calculate ln Lnull based on other information in the article, and then calculate LR using Equation (4),
thus allowing R2CS_app and R
2
CS_adj to be derived using Equations (6) and (8), respectively. For example, in a logistic
regression model, the logLnull value can be calculated using
lnLnull = E ln
(E
n
)
+ (n − E) ln
(
1 − En
)
, (12)
where E is the total number of outcome events. Of course, this assumes E and n are actually available in the article.
Similarly, for an exponential survival model (equivalent to a Poisson model with ln (survival time) as an offset), the
ln Lnull can be calculated using
lnLnull = E ln(𝜆) + 𝜆T = E ln
(E
T
)
+ E (13)
as long as 𝜆 (the constant hazard rate), E (the total number of events), and T (the total time at risk, eg, total person-years)
are available in the article. Note that, for survival models, packages such as SAS and Stata usually add a constant to the
reported log-likelihood to ensure it remains the same value regardless of the time scale used. For example, Stata adds the
sum of the ln (survival times) for the noncensored individuals to the reported ln Lmodel and ln Lnull, and so this constant
must be either consistently used or consistently removed in each of ln Lmodel and ln Lnull when deriving the LR value.
3.2 Using other pseudo-R2 statistics to derive R𝟐CS_adj
Sometimes other pseudo-R2 statistics are reported for logistic and survival models, rather than the Cox-Snell version
specified in Equation (6). In particular, because R2CS_app has a maximum value less than 1, Nagelkerke's R
2 is sometimes
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reported,34 which divides R2CS_app by the maximum value defined by 1 − exp
(
2 lnLnull
n
)
, as follows:
R2Nagelkerke_app =
R2CS_app
max
(
R2CS_app
) = R2CS_app
1 − exp
(
2 lnLnull
n
) . (14)
Recall that ln Lnull is derivable from other information, eg, using Equations (12) or (13) for logistic and exponential
(Poisson) models, respectively. When Nagelkerke's R2, ln Lnull, and n are available, the R2CS_app can be calculated by
rearranging Equation (14) to give
R2CS_app = R
2
Nagelkerke_app
(
1 − exp
(
2 lnLnull
n
))
, (15)
and then R2CS_adj calculated via Equation (8).
Another measure sometimes reported is McFadden's R2 37
R2McFadden_app = 1 −
lnLmodel
lnLnull
. (16)
As ln Lnull is often obtainable (see previous equation), when R2McFadden_app is reported, we can rearrange Equation (16) to
obtain ln Lmodel, and subsequently derive the LR statistic using Equation (4), the Cox-Snell R2CS_app from Equation (6), SVH
from Equation (7) (assuming the model's n and p are also provided), and finally R2CS_adj via Equation (8).
For proportional hazards survival models, O'Quigley et al suggested to modify R2CS_app by replacing n with the number
of events (E)38
R2ÓQuigley_app = 1 − exp
(−LR
E
)
. (17)
Therefore, if R2ÓQuigley_app and E were reported, the LR value could be found using
LR = −E ln
(
1 − R2ÓQuigley_app
)
, (18)
and subsequently, R2CS_app can be obtained using Equation (6), SVH using Equation (7), and finally R
2
CS_adj using
Equation (8).
Another measure increasingly being reported for survival models is Royston's measure of explained variation,39 which
is given by
R2Royston_app =
R2ÓQuigley_app
R2ÓQuigley_app +
(
𝜋2
6
)(
1 − R2ÓQuigley_app
) . (19)
When R2Royston_app is reported it can be used to obtain R
2
ÓQuigley_app by rearranging Equation (19) as
R2ÓQuigley_app =
− 𝜋
2
6 R
2
Royston_app(
1 − 𝜋26
)
R2Royston_app − 1
. (20)
This subsequently allows LR, R2CS_app, SVH and then R
2
CS_adj to be derived as explained previously. A similar measure
to R2Royston is Royston and Sauerbrei's R
2
D,40 which can be derived from their proposed D statistic (the ln(hazard ratio)
comparing two groups defined by the median value of the model's risk score in the population of application)
R2D_app =
𝜋
8D
2
𝜋2
6 +
𝜋
8D
2
. (21)
In examples shown by Royston,39 R2Royston_app and R
2
D_app are reasonably similar, and thus, we tentatively suggest R
2
D_app as
a proxy for R2Royston_app when only R
2
D_app (or D) is reported; though, we recognise that further research is needed on the
link between R2D_app and R
2
Royston.
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TABLE 2 Predicted values of the D statistic
and R2D from Equation (23) for selected values of
the C statistic (values taken from table 1 in the
work of Jinks et al41)
C D R𝟐D C D R𝟐D
0.50 0 0 0.72 1.319 0.294
0.52 0.11 0.003 0.74 1.462 0.338
0.54 0.221 0.011 0.76 1.61 0.382
0.56 0.332 0.026 0.78 1.765 0.427
0.58 0.445 0.045 0.80 1.927 0.470
0.60 0.560 0.070 0.82 2.096 0.512
0.62 0.678 0.099 0.84 2.273 0.552
0.64 0.798 0.132 0.86 2.459 0.591
0.66 0.922 0.169 0.88 2.652 0.627
0.68 1.05 0.208 0.90 2.857 0.661
0.70 1.182 0.25 0.92 3.070 0.692
3.3 Using values of the C statistic to derive R𝟐CS_adj
Jinks et al also proposed the following equation, based on empirical evidence, for predicting Royston's D (and thus
subsequently R2D_app) when only the C statistic is reported for a survival model41
D = 5.50(C − 0.5) + 10.26(C − 0.5)3. (22)
Table 2 provides values of D (and corresponding values of R2D_app from Equation (21)) predicted from Equation (22) for
selected values of the C statistic, as taken from the work of Jinks et al.41 Thus, if only the C statistic is reported, we can
use Equation (22) to predict Royston's D statistic and calculate R2D_app (using Equation (21)) as a proxy to R
2
Royston_app, and
then R2ÓQuigley_app, LR, R
2
CS_app and finally R
2
CS_adj computed sequentially using the equations given previously.
Further evaluation of the performance of Jinks' formula is required, eg, using simulation and across settings with dif-
ferent cumulative outcome incidences. Indeed, based on figure 5 in the work of Jinks et al,41 the potential error in the
predictions of D appears to increase as C increases, and is about +/− 0.25 when C is 0.8. Nevertheless, Equation (22)
serves as a good starting point and works well in our applied example (see Section 5.2.1). Further research is also needed
to ascertain how to predict R2CS from other measures, such as Somer's D statistic.
3.4 The anticipated value of R𝟐CS_adj may be small
It is important to emphasise that the Cox-Snell, R2CS, values for logistic and survival models are usually much lower than
for linear regression models, with values often less than 0.3. A key reason is that (unlike for linear regression) the R2CS_app
has a maximum value less than 1, defined by
max
(
R2CS_app
)
= 1 − exp
(
2 lnLnull
n
)
. (23)
This is because ln Lnull is itself bounded for binary and time-to-event outcomes (see Equations (12) and (13)). For example,
for a logistic regression model with an outcome proportion of 50%, using Equation (12) and an arbitrary sample size of
100, we have
lnLnull = E ln
(E
n
)
+ (n − E) ln
(
1 − En
)
= 50 ln
( 50
100
)
+ (100 − 50) ln
(
1 − 50100
)
= −69.315,
and therefore, using Equation (23),
max
(
R2CS_app
)
= 1 − exp
(
2 lnLnull
n
)
= 1 − exp
(−69.315
100
)
= 0.75.
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However, for an outcome proportion of 5%, themax(R2CS_app) is 0.33, and for an outcome proportion of 1%, themax(R
2
CS_app)
is 0.11. Therefore, especially in situations where the outcome proportion is low, researchers should anticipate a model
with a (seemingly) low R2CS_app value, and subsequently a low R
2
CS_adj value.
Low values of R2CS_app or R
2
CS_adj do not necessarily indicate poor model performance. Consider the following three
examples. First, Poppe et al used a Cox regression to develop a model (“PREDICT-CVD”) to predict the risk of future
CVD events within two years in patients with atherosclerotic CVD,42 and directly report an R2CS_app of 0.04. However,
the corresponding C statistic is 0.72, which shows discriminatory magnitude typical of many prognostic models used in
practice. Second, Hippisley-Cox and Coupland use the QResearch database to produce three models (QDiabetes) that
estimates the risk of future diabetes in a general population.43 In their validation of their “model A,” there were 27 311
incident cases of diabetes recorded in 1 322 435 women (3.77 cases per 1000 person-years) during follow-up, and the
reported R2Royston_app was 0.505. Using the approach described previously to convert R
2
Royston to LR, this leads to a R
2
CS_app of
0.02; however, the corresponding D statistic of 2.07 and C statistic of 0.89 are large. Third, in a risk prediction model for
venous thromboembolism (VTE) inwomen during the first 6 weeks after delivery,44 R2CS_app was 0.001 due to the extremely
low event risk (7.2 per 10 000 deliveries), but the model still had important discriminatory ability as the corresponding C
statistic was 0.70.
4 ADDITIONAL SAMPLE SIZE CRITERIA
Criterion (i) focuses on shrinkage of predictor effects, which is a multiplicative measure of overfitting (ie, on the relative
scale). Harrell suggests to also evaluate overfitting on the absolute scale and to check key model parameters are estimated
precsiely.15 We now address this with two further criteria.
4.1 Criterion (ii): ensuring a small absolute difference in the apparent
and adjusted R𝟐Nagelkerke
Our second criterion for minimum sample size is to ensure a small absolute difference (𝛿) between the model's apparent
and adjusted proportion of variance explained. We suggest using Nagelkerke's R2 for this purpose as, unlike the Cox-Snell
R2 value, it can range between 0 and 1, and so a small difference (say ≤ 0.05) can be ubiquitously defined. Based on
Equation (14), the difference in the apparent and adjusted Nagelkerke's R2 can be defined as
R2Nagelkerke_app − R
2
Nagelkerke_adj =
R2CS_app
max
(
R2CS_app
) − R2CS_adj
max
(
R2CS_app
)
=
R2CS_adj
SVH
− R2CS_adj
max
(
R2CS_app
)
=
R2CS_adj (1 − S𝑉 𝐻 )
SVH max
(
R2CS_app
) , (24)
where max(R2CS_app) = 1 − exp
(
2 lnLnull
n
)
, as shown in Equation (23).
Therefore, to meet sample size criterion (ii) and ensure the difference is less than a small value (say, 𝛿), we require
R2CSadj (1 − SVH)
SVH max
(
R2CSapp
) ≤ 𝛿. (25)
We generally recommend 𝛿 is ≤ 0.05, such that the optimism is Nagelkerke's percentage of variation explained is ≤ 5%.
Rearranging Equation (25), we find that
(1 − SVH)
SVH
≤
𝛿 max
(
R2CSapp
)
R2CSadj
,
RILEY ET AL. 1285
and therefore,
SVH ≥
R2CSadj
R2CSadj + 𝛿 max
(
R2CSapp
) . (26)
Equation (26) allows the researcher to calculate the required SVH to satisfy criterion (ii), conditional on prespecifying the
model's anticipated R2CS_adj (as they did for criterion (i)) and also the value of max(R
2
CSapp
) as outlined for Equation (23).
Then, sample size equation (11) can be used to derive the sample size needed to satisfy criterion (ii). This is only necessary
when the calculated value of SVH from Equation (26) is larger than that chosen for criterion (i), as then the sample size
required to meet criterion (ii) will be larger than that for criterion (i).
For example, consider the development of a logistic regression model with anticipated R2CS_adj of at least 0.1, and in a
setting with the outcome proportion of 5%, such that the max(R2CS_app) is 0.33. Then, to ensure 𝛿 is ≤ 0.05, we require
SVH ≥
R2CSadj
R2CSadj + 𝛿 max
(
R2CSapp
) = 0.10.1 + (0.05 × 0.33) = 0.858.
Therefore, SVH must be at least 0.86 to meet criterion (ii). As this is lower than the recommended value of at least 0.90 to
meet criterion (i), no further work is required. However, had the anticipated R2CS_adj been 0.2, then
SVH ≥
0.2
0.2 + (0.05 × 0.33) = 0.924.
As this is higher than 0.90, we would need to reapply sample size equation (11) using 0.924, rather than 0.90, to obtain a
sample size that meets both criteria (i) and (ii).
4.2 Criterion (iii): ensure precise estimate of overall risk (model intercept)
For logistic and time-to-event models, it is fundamental that the available sample size can precisely estimate the overall
risk in the population by key time-points of interest. Oneway to examine this is to calculate themargin of error in outcome
proportion estimates (?̂?) for a null model (ie, no predictors included). For example, for a binary outcome, an approximate
95% confidence interval for the overall outcome proportion is
?̂? ± 1.96
√
?̂?(1 − ?̂?)
n .
Therefore, the absolute margin of error (𝛿) is 1.96
√
?̂?(1−?̂?)
n , which leads to
n =
(1.96
𝛿
)2
?̂?(1 − ?̂?) . (27)
This is largest when the outcome proportion is 0.5. We require 96 individuals to ensure a margin of error ≤ 0.1 when the
true value is 0.5.15 However, we recommend amore stringentmargin of error≤ 0.05, which, when the outcome proportion
is 0.5, requires
n =
(1.96
0.05
)2
0.5(1 − 0.5) = 384.2,
and thus, 385 participants (and hence, about 193 events) are required. If the outcome proportion is 0.1, then we require
139 subjects to ensure a margin of error ≤ 0.05, whilst an outcome proportion of 0.2 requires 246 subjects.
These sample sizes aim to ensure precise estimation of the overall risk in the population of interest. Strictly speaking,
we are more interested in precise estimation of the mean risk in an actual model including multiple predictors. If we
centre predictors at their mean value, then the model's intercept is the logit risk for an individual with mean predictor
values. The corresponding risk for this individual will often be very similar (though not identical) to the mean risk in
the overall population. Furthermore, the variance of the estimated risk for this individual will be approximately ?̂?(1−?̂?)n .*
*As obtained by inversing the information matrix X'V−1X and replacing individual variances defined by pi(1-pi) with a constant variance defined by
?̂?(1 − ?̂?).
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Thus, it follows that Equation (27) is also a good approximation to the sample size required to precisely estimate themean
risk in a model containing predictors centred at their mean.
For time-to-event data, we could consider the precision of the estimated cumulative incidence (outcome risk) at a key
time point of interest. A simple (and therefore practical) approach is to assume an exponential survival model, for which
the estimated cumulative incidence function is F(t) = 1 − exp(−?̂? t), where ?̂? is the estimated rate (number of events per
person-year). An approximate 95% confidence interval for the estimated F(t) is 1− exp
(
−
(
?̂? ± 1.96
√
?̂?
T
)
t
)
, where T is
the total person-years of follow-up. Therefore, to ensure a small absolute margin of error, such that the lower and upper
bounds of the confidence interval are ≤ 𝛿 (eg, 0.05) of the true value, we must ensure both the following are satisfied:
− exp
(
−
(
?̂? + 1.96
√
?̂?
T
)
t
)
+ exp(−?̂? t) ≤ 𝛿
− exp(−?̂? t) + exp
(
−
(
?̂? − 1.96
√
?̂?
T
)
t
)
≤ 𝛿.
(28)
For example, for a constant event rate of 0.10 (10 events per 100 person-years), then by 10 years, the outcome risk is F(10)
= 1 − exp (−0.1 × 10) = 0.632. Then, 2366 person-years of follow-up (and thus 0.1 × 2366 ≈ 237 events) are needed to
provide a confidence interval, which has a maximum absolute error of 0.05 from the true value. That is,
1 − exp
(
−
(
?̂? ± 1.96
√
?̂?
T
)
t
)
= 1 − exp
(
−
(
0.10 ± 1.96
√
0.10
2366
)
10
)
= 0.582 to 0.676.
Thus, Equation (28) is satisfied, as both the lower and upper bounds are≤ 0.05 of the true value of 0.632.More generally, to
avoid assuming simple survival distributions like the exponential, Harrell suggests using the Dvoretzky-Kiefer-Wolfowitz
inequality to estimate the probability of a chosen margin of error anywhere in the estimated cumulative incidence
function.15,45
5 WORKED EXAMPLES
To summarise our sample size approach for researchers, we provide a step-by-step guide in Figure 1. The sample size (and
corresponding number of events and EPP) that meets criteria (i) to (iii) provides the minimum sample size required for
model development. We now present two worked examples to illustrate our approach.
5.1 A diagnostic prediction model for chronic Chagas disease
Our first example considers the minimum sample size required for developing a diagnostic model for predicting a binary
outcome (disease: yes or no). Brasil et al developed a logistic regression model containing 14 predictor parameters for
predicting the risk of having chronic Chagas disease in patients with suspected Chagas disease.46 Upon external validation
in a cohort of 138 participants containing 24 with Chagas disease, the model had an estimated C statistic of 0.91 and an
R2Nagelkerke_app of 0.48. Consider that a researcher wants to update this model and improve the predictive performance. Our
sample size approach can be applied as follows.
5.1.1 Steps 1 and 2: identifying values for p, R𝟐CS_adj, and max(R
𝟐
CS_app)
Assume that the researcher has identified (eg, based on recent studies) 10 additional predictor parameters that they wish
to add to the original model. Thus, in total, the number of predictor parameters, p, is 24. The next step is to identify a
sensible value for the anticipated Cox-SnellR2adj. To achieve this, we can convert theR
2
Nagelkerke_app value for Brasil's existing
model into aR2CS_app value. Assume the disease prevalence is 17.4%, as in the Brasil validation study, and use Equation (12)
to calculate the log-likelihood for the null model in Brasil's validation study
lnLnull = E ln
(E
n
)
+ (n − E) ln
(
1 − En
)
= 24 ln
( 24
138
)
+ (138 − 24) ln
(
1 − 24138
)
= −63.761.
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FIGURE 1 Summary of the steps involved in calculating the minimum sample size required for developing a multivariable prediction
model for binary or time-to-event outcomes
Hence, the max(R2CSapp ) = 1 − exp
(
2 lnLnull
n
)
= 1 − exp
(
2×−63.761
138
)
= 0.60. Now, we can use Equation (15) to obtain
R2CS_app = R
2
Nagelkerke_app
(
max
(
R2CSapp
))
= 0.48 × 0.60 = 0.288.
This apparent Cox-Snell value of 0.288 can be directly used as an estimate of the model's R2CS_adj, as it was obtained in a
different data set to that used for model development. Therefore no adjustment is needed, because R2CS_app= R
2
CS_adj here.
5.1.2 Step 3: criterion (i) - ensuring a global shrinkage factor of 0.9
Let us assume 0.288 is a lower bound for the R2CS_adj of our new model. We now use Equation (11) to estimate the sample
size required to ensure an expected shrinkage factor (SVH = 0.90) conditional on a number of predictor parameters (p= 24)
n = p
(SVH − 1) ln
(
1 −
R2CSadj
SVH
) = 24
(0.90 − 1) ln
(
1 − 0.2880.90
) = 622.31.
Thus, 623 participants are required to meet criterion (i).
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5.1.3 Step 4: criterion (ii) - ensuring a small absolute difference in the apparent
and adjusted R𝟐Nagelkerke
To meet criterion (ii), we first need to calculate the shrinkage factor required to ensure a small difference of 0.05 or less
in the apparent and adjusted R2Nagelkerke. Using Equation (26), we obtain
SVH ≥
R2CSadj
R2CSadj + 𝛿 max
(
R2CSapp
) = 0.2880.288 + (0.05 × 0.60) = 0.906.
This is more stringent than the 0.90 assumed for criterion (i). Therefore, we need to reapply Equation (11) to estimate the
sample size required conditional on SVH = 0.906 (rather than 0.90)
n = p
(SVH − 1) ln
(
1 −
R2CSadj
SVH
) = 24
(0.906 − 1) ln
(
1 − 0.2880.906
) = 667.41.
Therefore, 668 subjects are required to meet criterion (ii), exceeding the 623 subjects required for criterion (i).
5.1.4 Step 5: criterion (iii) - ensure precise estimate of overall risk (model intercept)
Assuming the prevalence of Chagas disease is 17.4% (as observed from the Brasil validation study), then to ensure we
estimate this with a margin of error ≤ 0.05, we require (using Equation (27))
n =
(1.96
0.05
)2
0.174 (1 − 0.174) = 220.85
and thus 221 subjects. This is far fewer than the sample size required to meet criteria (i) and (ii).
5.1.5 Step 6: minimum sample size that ensures all criteria are met
The largest sample size required was 668 subjects to meet criterion (ii), and so this provides the minimum sample size
required for developing our new model. It corresponds to 668 × 0.174 = 116.2 events, and an EPP of 116.2/24 = 4.84,
which is considerably lower than the “EPP of at least 10” rule of thumb.
5.2 A prognostic model to predict a recurrence of VTE
Our second example considers the sample size required to develop a prognostic model with a time-to-event outcome.
Ensor et al developed a prognostic time-to-event model for the risk of a recurrent VTE following cessation of therapy for
a first VTE.47 The sample size was 1200 participants, with a median follow-up of 22 months, a total of 2483 person-years
of follow-up, and 161 (13.42% of) individuals had a VTE recurrence by end of follow-up.47 The model included predictors
of age, gender, site of first clot, D-dimer level, and the lag time from cessation of therapy until measurement of D-dimer
(often around 30 days). These predictors corresponded to six parameters in the model, which was developed using the
flexible parametric survival modelling framework of Royston and Parmar48 and Royston and Lambert.49 Although Ensor's
model performed well on average, the model's predicted risks did not calibrate well with the observed risks in some
populations.47 Therefore, new research is needed to update and extend this model, eg, by including additional predictors.
We now identify suitable sample sizes to inform such research.
5.2.1 Steps 1 and 2: identifying values for p, R𝟐CS_adj and max(R
𝟐
CS_app)
Assume that there are 25 potential predictor parameters for inclusion in the new model, and thus, p = 25. We next need
to identify suitable values for 𝑅2CS_adj and max(𝑅
2
CS_app).
Calculatingmax(R𝟐CS_app)
For the Ensor model, R2CS_app was not reported but we should expect it to be quite small because the maximum value
of R2CS_app is low. For example, assuming (for simplicity) an exponential survival model was fitted to the Ensor data, then
using Equation (13), we have
lnLnull = E ln
(E
T
)
+ E = 161 ln(161∕2483) + 161 = −279.47,
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and therefore, using Equation (23),
max
(
R2CS_app
)
= 1 − exp
(
2 lnLnull
n
)
= 1 − exp
(−2 × 279.47
1200
)
= 0.37.
Thus, max(R2CS_app) is considerably less than 1.
Obtaining a sensible value for R𝟐CS_adj from the study authors
As R2CS_app was not reported for the Ensor model, we need to obtain it. We contacted the original authors who told us
their model's R2CS_app was 0.056 in the development data set. Thus, let us use this value to derive R
2
adj from Equation (8).
Based on Ensor's sample size of 1200, and six predictor parameters, we obtain
R2CS_adj = SVHR
2
CS_app =
⎛⎜⎜⎜⎝1 +
p
n ln
(
1 − R2CS_app
)⎞⎟⎟⎟⎠R
2
CS_app =
(
1 + 61200 ln (1 − 0.056)
)
0.056 = 0.051.
Hence, when developing a newmodel in this field, we could assume 0.051 is a lower bound for the expected R2CS_adj of the
new model. This corresponds to Nagelkerke's proportion variation explained of R2CS_adj∕max(R
2
CS_app) ≈ 0.051/0.37 = 0.14
(or 14%).
Calculating a sensible value for R𝟐CS_adj from other reported information
For illustration, we also consider how R2CS_app could have been estimated indirectly from other available information.
The model's reported C statistic was 0.69, and so we can use Equation (22) to predict the corresponding D statistic
D = 5.50 (C − 0.5) + 10.26(C − 0.5)3 = 5.50 (0.69 − 0.5) + 10.26(0.69 − 0.5)3 = 1.115.
The corresponding R2D_app can be derived from Equation (21)
R2D_app =
𝜋
8D
2
𝜋2
6 +
𝜋
8D
2
=
𝜋
8 1.115
2
𝜋2
6 +
𝜋
8 1.115
2
= 0.229.
Taking R2D_app as a proxy for R
2
Royston_app, we can then use Equation (20) to obtain
R2ÓQuigley_app =
− 𝜋
2
6 R
2
Royston_app(
1 − 𝜋26
)
R2Royston_app − 1
=
− 𝜋
2
6 0.229(
1 − 𝜋26
)
0.229 − 1
= 0.328.
Next, we can use R2ÓQuigley_app and the number of reported events (E = 161) to derive the LR statistic from Equation (18)
LR = −E ln
(
1 − R2ÓQuigleyapp
)
= −161 ln (1 − 0.328) = 64.05.
Using Equation (6), this corresponds to
R2CS_app = 1 − exp
(−LR
n
)
= 1 − exp
(−64.05
1200
)
= 0.052.
Thus, based on using the reported C statistic, an indirect estimate of the R2CS_app is 0.052 for the Ensor model. This is
reassuringly close to the estimate of 0.056 provided directly by the study authors.
5.2.2 Step 3: criterion (i) - ensuring a global shrinkage factor of 0.9
Equation (11) can now be applied to derive the required sample size to meet criterion (i). Using an R2CS_adj of 0.051, for a
model with 25 predictor parameters and a targeted expected shrinkage of 0.9, the sample size required is
n = p
(SVH − 1) ln
(
1 −
R2CS_adj
SVH
) = 25
(0.9 − 1) ln
(
1 − 0.0510.9
) = 4285.5
and thus 4286 participants.
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5.2.3 Step 4: criterion (ii) - ensuring a small absolute difference in the apparent
and adjusted R𝟐Nagelkerke
To meet criterion (ii), we first need to calculate the shrinkage factor required to ensure a small difference of 0.05 or less
in the apparent and adjusted R2Nagelkerke. Recall, assuming an exponential model for simplicity, we calculated that the
max(R2CSapp ) = 0.37. Then, using Equation (26), we obtain
SVH ≥
R2CSadj
R2CSadj + 𝛿 max
(
R2CSapp
) = 0.0510.051 + (0.05 × 0.37) = 0.73.
This is less stringent than the 0.90 assumed for criterion (i), and so no further sample size calculation is required to meet
criterion (ii).
5.2.4 Step 5: criterion (iii) - ensure precise estimate of overall risk
Assuming a simple exponentialmodel, we can check thewidth of the confidence interval for the overall risk at a particular
time point based on the sample size identified, using the approach outlined in Section 4.2. Ensor et al47 reported an overall
VTE recurrence rate of 161/2483 = 0.065, with an average follow-up of 2.07 years. Therefore, assuming 𝜆 is 0.065 in our
new study, and that a predicted risk at 2 years is of key interest, an exponential survival model would give the cumulative
incidence of F(2)= 1− exp (−0.065× 2)= 0.122. Based on the calculated sample size of 4286 participants from criterion (i),
and thus an estimated 4286×2.07 = 8872 person-years of follow-up, the 95% confidence interval would be
1 − exp
(
−
(
?̂? ± 1.96
√
?̂?
T
)
t
)
= 1 − exp
(
−
(
0.065 ± 1.96
√
0.065
8872
)
2
)
= 0.113 to 0.131.
This is reassuringly narrow, and satisfies Equation (28) as both the lower and upper bounds are well within an error of
0.05 of the true value of 0.122.
5.2.5 Step 6: minimum sample size that ensures all criteria are met
The largest sample size requiredwas 4286 participants tomeet criterion (i), which therefore provides theminimumsample
size required for developing our new model. This assumes the new cohort will have a similar follow-up, censoring rate,
and event rate to that reported by Ensor et al, where the mean follow-up per person was 2.07 years, 13.42% of individuals
had a VTE recurrence by end of follow-up, and the event rate was 0.065.47
Then, the required 4286 participants corresponds to about 4286 × 2.07 = 8872 person-years of follow-up, and
8872 × 0.065 ≈ 577 outcome events, and thus an EPP of 577/25 ≈ 23. This is over twice the “EPP of at least 10” rule of
thumb. Figure 2 shows that an EPP of 10 only ensures a shrinkage factor of 0.79, which would reflect relatively large
overfitting.
5.2.6 What if the sample size is not achievable?
If a researcher was restricted in their total sample size, for example, by the time and cost of a new cohort study, then a
sample size of 4286 may not be practical. In this situation, we do not recommend reducing sample size by decreasing
SC below 0.9 (as this would reflect larger overfitting) or by assuming a larger R2CS_adj value (as this is anticonservative
for criterion (i)). Rather, to ensure an SVH of 0.9 (ie, an expected shrinkage of 10%), the researcher should lower p by
reducing the number of candidate predictors. For example, predictors could be prioritised based on previous evidence (eg,
systematic reviews). After data collection, unsupervised learning techniques such as principal component analysis may
be useful, which are blinded to the outcome data. Figure 3 shows how changing p changes the required sample size to
meet criterion (i). For example, if a researcher was restricted to a sample size of about 2000 participants, then they would
need to reduce p to 12 to ensure an expected shrinkage of 0.90. This is because, for an SVH of 0.9 and R2CS_adj of 0.051, the
sample size required is
n = p
(SVH − 1) ln
(
1 −
R2CS_adj
SVH
) = 12
(0.9 − 1) ln
(
1 − 0.0510.9
) = 2057
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FIGURE 2 Events per predictor parameter required to achieve various expected shrinkage (SVH) values for a new prediction model of
venous thromboembolism recurrence risk with an assumed R2CS_adj of 0.051 [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 3 Sample size required (based on Equation (11)) for a particular number of predictor parameters (p) to achieve a particular value
of expected shrinkage (SVH), for a new prediction model of venous thromboembolism recurrence risk with an assumed R2CS_adj of 0.051
[Colour figure can be viewed at wileyonlinelibrary.com]
and so now close to 2000. Figure 3 also shows how larger values of SVH require larger sample sizes; in particular, the
increase in sample size required is substantial when moving from SVH of 0.90 to 0.95. Values of SVH < 0.9 lead to lower
sample sizes, but come at the cost of larger expected overfitting, and so are not recommended. Therefore, targeting a value
of SVH of 0.9 would seem a pragmatic choice.
6 POTENTIAL ADDITIONAL CRITERION: PRECISE ESTIMATES OF
PREDICTOR EFFECTS
Ideally, predictions should also be precise across the entire spectrum of predicted values, not just at themean. This is chal-
lenging to achieve, but is helped by ensuring the sample size will give precise estimates of the effects of key predictors;50
hence, this may form a further criterion for researchers to check (ie, in addition to criteria (i) to (iii)). Briefly, for a par-
ticular predictor of a binary or time-to-event outcome, the sample size required to precisely estimate its association with
the outcome (ie, an odds ratio or hazard ratio) depends on the assumed magnitude of this effect, the variability of the
predictor's values across subjects, the predictor's correlation with other predictors in the model, and the overall outcome
proportion in the study.51-53 Ideally, we want to ensure a sample size that gives a precise confidence interval around the
predictor's effect estimate.54 However, this is taxing, as closed-form solutions for the variance of adjusted log odds ratio
or hazard ratios, from logistic and Cox regression, respectively, are nontrivial. One solution is to use simulation-based
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evaluations.54,55 However, perhaps a more practical option is to utilise readily available power-based sample size calcula-
tions that calculate the sample size required to detect (based on statistical significance) a predictor's effect for a chosen
type I error level (eg, 0.05) and power.51-53,56 As such sample size calculations are likely to be less stringent than those
based on confidence interval width (especially for predictors with large effect sizes), we might use a high power, say of
95%, in the calculation.
Checking sample size for predictor effects will be laborious with many predictors, and so it may be practical to focus
on the subset of key predictors with smallest variance of their values, as these predictors will have the least precision.
In particular, when there are important categorical predictors but with few subjects and/or outcome events in some cat-
egories, substantially larger sample sizes may be needed to avoid separation issues (ie, no event or nonevents in some
categories).57 In addition, any predictors whose effect is small (and thus harder to detect), but still important, maywarrant
special attention.
For example, returning to theVTEpredictionmodel fromSection 5.2, a key predictor in the originalmodel by Ensor et al
was age,47 with an adjusted log hazard ratio of −0.0105. Although this is close to zero, as age is on a continuous scale, the
impact of age on outcome risk is potentially large; for example, it corresponds to an adjusted hazard ratio of 0.66 comparing
two individuals aged 40 years apart. Based on the results presented by Ensor et al,47 the standard deviation of agewas 15.21
and the overall outcome occurrence by end of follow-up was 13.5%. Based on these values, and assuming other included
predictors explain 20% of the variation in age, then the sample size approach of Hsieh and Lavori52 suggests 4718 subjects
are required to have 95% power to detect a prognostic effect for age. This is larger than the 4286 subjects required to meet
criterion (i), and so, to be extra stringent beyond criteria (i) to (iii), the researcher might raise the recommended sample
size to 4718 subjects, if possible.
7 DISCUSSION
Sample size calculations for prediction models of binary and time-to-event outcomes are typically based on blanket rules
of thumb, such as at least 10 EPP, which generates much debate and criticism.14,16,57 In this article, building on our related
work for linear regression,10 we have proposed an alternative approach that identifies the sample size, events and EPP
required to meet three key criteria, which minimise overfitting whilst ensuring precise estimates of overall outcome risk.
Criterion (i) aims to ensure the optimism of predictor effect estimates is small, as defined by a global shrinkage factor of
≥ 0.9. This idea extends the work of Harrell who suggests that, after a model is developed, if the shrinkage estimate “falls
below 0.9, for example, we may be concerned with the lack of calibration the model may experience on new data.”15 Our
premise is the same, except we focused on calculating the expected shrinkage before data collection, to inform sample
size calculations for a new study. Criterion (ii) extends this idea to ensure the optimism is small on the R2Nagelkerke scale,
such that there is a difference of≤ 5% in the apparent and adjusted percentage of variation explained by themodel. Lastly,
criterion (iii) ensures the sample size will precisely estimate the overall outcome risk, which is fundamental.
By utilising the model's anticipated Cox-Snell R2, the sample size calculations are essentially tailored to the model and
setting at hand, because the Cox-Snell R2 reflects many factors including the outcome proportion (ie, outcome prevalence
or cumulative incidence) and the overall fit (performance) of the model. It therefore better reflects the trait of a particular
model and setting at hand rather than a blanket EPP rule.16 In our examples, the sample sizes required often differed
considerably from an EPP of 10, reinforcing the idea that this rule is too simplistic.57 Indeed, the required EPP was much
higher (23) in our second example than our first (4.8), illustrating the problem with a blanket EPP rule trying to cover all
situations.14,16-18
Section 3 also showed how to obtain a realistic value for Cox-Snell R2 based on previous models to make our proposal
more achievable in practice. If no previous prediction model exists for the outcome and setting of interest, then informa-
tion might be used from studies in a related setting or using a different but similar outcome definition or time points to
those intended for the new model. Information can also be borrowed from predictor finding studies (eg, studies aiming
to estimate the prognostic effect of a particular predictor adjusted for other predictors58). Typically, these studies apply
multivariable modelling, and although mainly focused on predictor effect estimates, they often report the C statistic and
pseudo-R2 values.
Further research is needed to help researchers when there are no existing studies or information to identify a sensible
value of the expected Cox-Snell R2. Medical diagnosis and prediction of health-related outcomes are, generally speaking,
low signal-to-noise ratio situations. It is not uncommon in these situations to see R2Nagelkerke values in the 0.1 to 0.2 range.
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Therefore, in the absence of any other information, we suggest that sample sizes be derived assuming the value of R2CS_adj
corresponds to an R2Nagelkerke of 0.15 (ie,
R2CSadj
max(R2CSadj )
= 0.15). An exception is when predictors include “direct” (mechanistic)
measurements, such as including the baseline version of the binary or ordinal outcome (eg, including smoking status at
baselinewhen predicting smoking status at 1 year), or directmeasures of the processes involved (eg, including physiologic
function of patients in intensive care when predicting risk of death within 48 hours). Then, in this special situation,
an R2Nagelkerke = 0.5 may be a more appropriate default choice.
The rule of having an EPP of at least 10 stems from limited simulation studies examining the bias and precision of
predictor effects in the prediction model.11-13 Jinks et al41 alternatively developed sample size formulae for a time-to-event
prediction model based on the D statistic.40 They suggest to predefine the D statistic that would be expected, and then,
based on a desired significance or confidence interval width, their formulae provide the number of events required to
achieve this. However, their method does not account for the number of candidate predictors and does not consider the
potential for overfitting when developing a model. Our sample size calculations address this, and are meant to be used
before any data collection. In situations where a development data set is already available, containing a specific number
of participants and predictors, our criteria could be used to identify whether a reduction in the number of predictors
is needed before starting model development. Indeed, Harrell already illustrated this concept by using the shrinkage
estimate from the full model (including all predictors) to gauge whether the number of predictors should be reduced via
data reduction techniques.15 Ideally, this should be done blind to the estimated predictor effects (ie, just calculate the
shrinkage factor for the full model, but do not observe the predictor effect estimates and associated p-values), as otherwise
decisions about predictor inclusion are influenced by a “quick look” at the effect estimates from the full model results.
Similarly, when planning to use a predictor selection method (such as backwards selection) during model development,
researchers should define p as the total number of parameters due to all predictors considered (screened), and not just
the subset that are included in the final model.59 As Harrell notes,15 the value of p should be honest.
Section 6 also highlighted the potential additional requirement to ensure precise estimates of key predictor effects.
In particular, special attention may be given to those predictors with strong predictive value (and thus most influential
to the predicted outcome risk), especially if the variance in their values is small, or when events or nonevents in some
categories of the predictor are rare, as this leads to larger sample sizes. For example, van Smeden et al highlighted that
“separation” between events and nonevents is an important consideration toward the required sample size, which occurs
when a single predictor (or a linear combination of multiple predictors) perfectly separates all events from all nonevents,
and thus causes estimation difficulties.57 This may lead to substantially larger EPP to resolve the issue (eg, so that all
categories of a predictor have both events and nonevents). For such reasons, we labelled our criteria (i) to (iii) proposal
as the “minimum” sample size required.
Further research should identify howour sample size criteria relates to that of thework of van Smeden et al, who focused
on sample size in regards to the mean squared error in predictions from the model.60 Specifically, they use simulation
to evaluate the characteristics that influence the mean squared prediction error of a logistic model, and identify that the
outcome proportion and number of predictors are important,60 in addition to total sample size. This leads to a sample size
equation tominimise rootmean-squared prediction error in a newmodel development study. Harrell also suggested using
simulation to inform sample size, and illustrates this for a logistic regressionmodel with a single predictor.15 For example,
one could simulate a very large dataset from an assumed prediction model, and quantify the mean square (prediction)
error and mean absolute (prediction) error of a model developed from this data set. Then, repeat this process each time
removing an individual at random, until a sample size is identified below which the mean squared (prediction) error is
unacceptable.
In summary, we have proposed criteria for identifying theminimum sample size requiredwhen developing a prediction
model for binary or time-to-event outcomes. We hope this, and our related paper,10 encourages researchers to move away
from rules of thumb, and to rather focus on attaining sample sizes that minimise overfitting and ensure precise estimates
of overall risk within the model and setting of interest. We are currently writing software modules to implement the
approach.
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